2017
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone C, Brown NJ. Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. Immunology And Allergy Clinics Of North America 2017, 37: 483-495. PMID: 28687104, DOI: 10.1016/j.iac.2017.04.006.Peer-Reviewed Original ResearchConceptsDrug-induced angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorNon-β-lactam antibioticsNonsteroidal antiinflammatory agentsNonallergic angioedemaSubstance PTherapeutic decisionsAngioedemaAntiinflammatory agentsLactam antibioticsOther DrugΒ-lactam antibioticsDrugsPatientsLeukotrienesBradykininGenetic variantsAntibioticsInhibitorsAngiotensinProstaglandinsAgentsHistamineMainstay
2010
Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro
Adam A, Montpas N, Keire D, Désormeaux A, Brown NJ, Marceau F, Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31: 5741-5748. PMID: 20427081, PMCID: PMC2896062, DOI: 10.1016/j.biomaterials.2010.03.074.Peer-Reviewed Original ResearchConceptsContact system activationAnaphylactoid reactionsOversulfated chondroitin sulfateSystem activationSevere anaphylactoid reactionPlasma contact systemHuman plasmaInflammatory peptidesChondroitin sulfateEnzyme inhibitorsBK releaseDrug AdministrationBradykininHeparinSignificant correlationDefinitive evidenceDextran sulfatePlasma dilutionActivationConclusionPatientsPathophysiologyKininsAdministrationPlasmaIncreased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism
Fong P, Stafforini DM, Brown NJ, Pretorius M. Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism. Free Radical Biology And Medicine 2010, 49: 301-305. PMID: 20423727, PMCID: PMC2916026, DOI: 10.1016/j.freeradbiomed.2010.04.023.Peer-Reviewed Original ResearchConceptsForearm blood flowHypertensive subjectsL-NMMAIsoprostane releaseBlood flowOxidative stressBasal forearm blood flowNitric oxide-independent mechanismEndothelium-independent mechanismNO synthase inhibitorEffect of bradykininMonomethyl-L-arginineIntraarterial bradykininPotent vasodilatorSynthase inhibitionSynthase inhibitorBradykininNitric oxideDependent mechanismReactive oxygen speciesHuman vasculatureSignificant increaseNitroprussideSubjectsOxygen species
2008
Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition
Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV, Brown NJ. Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition. Hypertension 2008, 51: 454-459. PMID: 18180402, PMCID: PMC2581632, DOI: 10.1161/hypertensionaha.107.102574.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngiotensin-Converting Enzyme InhibitorsBlood PressureBradykininDrug SynergismEnalaprilatEndothelium, VascularFemaleForearmGenotypeHumansInjections, Intra-ArterialMaleMethacholine ChlorideNitroprussidePolymorphism, GeneticReceptor, Bradykinin B2Regional Blood FlowSex FactorsTissue Plasminogen ActivatorVascular ResistanceVasodilationVasodilator AgentsConceptsForearm blood flowT-PA releaseForearm vascular resistanceVascular resistanceBlood flowBlood pressureTissue-type plasminogen activator releaseBasal forearm blood flowAngiotensin-Converting Enzyme InhibitionGenotype groupsNet t-PA releaseReceptor-mediated vasodilationBasal forearm vascular resistanceSystolic blood pressureBody mass indexIntra-arterial bradykininEffect of bradykininDegradation of bradykininPlasminogen activator releaseEnzyme inhibitionMass indexVascular responsesActivator releaseBradykininWhite American subjects
2007
The Bradykinin Type 2 Receptor BE1 Polymorphism and Ethnicity Influence Systolic Blood Pressure and Vascular Resistance
Pretorius MM, Gainer JV, Van Guilder GP, Coelho EB, Luther JM, Fong P, Rosenbaum DD, Malave HA, Yu C, Ritchie MD, Vaughan DE, Brown NJ. The Bradykinin Type 2 Receptor BE1 Polymorphism and Ethnicity Influence Systolic Blood Pressure and Vascular Resistance. Clinical Pharmacology & Therapeutics 2007, 83: 122-129. PMID: 17522594, DOI: 10.1038/sj.clpt.6100250.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack or African AmericanBlood Flow VelocityBlood PressureBradykininDose-Response Relationship, DrugFemaleForearmGene FrequencyGenotypeHumansInfusions, Intra-ArterialMaleNitroprussidePhenotypePolymorphism, GeneticReceptor, Bradykinin B2Regional Blood FlowVascular ResistanceVasodilator AgentsWhite PeopleConceptsSystolic blood pressureForearm vascular resistanceVascular resistanceBlood pressureEndothelium-independent agonist sodium nitroprussideEndothelium-dependent agonist bradykininIntrabrachial artery infusionsLeft ventricular massBradykinin B2 receptor geneB2 receptor geneNormotensive subjectsVentricular massPulse pressureB2 receptorsAgonist bradykininSodium nitroprussideReceptor geneBradykininGroupPolymorphismInfusionWhite AmericansNitroprussideBaselineBlack Americans
2006
Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema
Byrd JB, Adam A, Brown NJ. Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Immunology And Allergy Clinics Of North America 2006, 26: 725-737. PMID: 17085287, DOI: 10.1016/j.iac.2006.08.001.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaAngiotensin converting enzyme (ACE) inhibitorsEnzyme inhibitor usersNon-ACE pathwaysInhibitor usersAdverse eventsClinical recognitionSubstance PAssociated angioedemaEnzyme inhibitorsAngioedemaDefective degradationNonsmokersAngiotensinSmokersPathogenesisWhite AmericansBradykininIncidence
2005
Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men
Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men. Arteriosclerosis Thrombosis And Vascular Biology 2005, 25: 2435-2440. PMID: 16166566, DOI: 10.1161/01.atv.0000186185.13977.94.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAngiotensin-Converting Enzyme InhibitorsBlood PressureBradykininEnalaprilatFemaleHumansLuteal PhaseMaleMethacholine ChlorideMiddle AgedNitroprussideParasympathomimeticsPeptide FragmentsPeptidyl-Dipeptidase APostmenopausePremenopauseRegional Blood FlowSex CharacteristicsTissue Plasminogen ActivatorVasodilator AgentsConceptsT-PA releaseForearm blood flowBasal t-PA releaseNet t-PA releaseTissue plasminogen activator releasePostmenopausal womenPlasminogen activator releaseOlder menPremenopausal womenMenopausal statusActivator releaseIntra-arterial enalaprilatEffect of ACEIEndogenous bradykininHormone replacementExogenous bradykininBlood flowACEIBradykininEnalaprilatWomenYoung menMenEnzyme inhibitionRelease
2003
Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin
Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin. Circulation 2003, 107: 579-585. PMID: 12566370, DOI: 10.1161/01.cir.0000046268.59922.a4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngiotensin-Converting Enzyme InhibitorsBlood Flow VelocityBradykininBradykinin Receptor AntagonistsDose-Response Relationship, DrugEnalaprilatEndothelium, VascularFemaleFibrinolysisForearmHumansInfusions, Intra-ArterialMaleMethacholine ChlorideMuscarinic AgonistsRegional Blood FlowSmokingTissue Plasminogen ActivatorVascular ResistanceConceptsForearm blood flowNet t-PA releaseT-PA releaseEndothelial t-PA releaseHoe 140T-PA responseEndogenous bradykininACE inhibitionExogenous bradykininTissue-type plasminogen activator releaseReceptor antagonist HOE 140Angiotensin-Converting Enzyme InhibitionBradykinin receptor antagonist HOE 140Effects of enalaprilatIntra-arterial enalaprilatIntra-arterial infusionPlasminogen activator releaseEnzyme inhibitionFBF responseVascular resistanceBlood flowActivator releaseEnalaprilatBradykininMethacholine
2002
Ethnicity Affects Vasodilation, but Not Endothelial Tissue Plasminogen Activator Release, in Response to Bradykinin
Rosenbaum DA, Pretorius M, Gainer JV, Byrne D, Murphey LJ, Painter CA, Vaughan DE, Brown NJ. Ethnicity Affects Vasodilation, but Not Endothelial Tissue Plasminogen Activator Release, in Response to Bradykinin. Arteriosclerosis Thrombosis And Vascular Biology 2002, 22: 1023-1028. PMID: 12067915, DOI: 10.1161/01.atv.0000017704.45007.1d.Peer-Reviewed Original ResearchConceptsForearm blood flowFibrinolytic functionSodium nitroprussideEffect of ethnicityAge-matched normotensive subjectsTissue plasminogen activator antigenTissue plasminogen activator releaseDoses of bradykininPlasminogen activator antigenPlasminogen activator releaseFBF responseVasodilator responseNormotensive subjectsBrachial arteryIndependent agonistsArterial samplesBlood flowAntigen releaseActivator releaseBradykininMethacholineAcetylcholineWhite AmericansNitroprussideBlack AmericansSmoking Impairs Bradykinin-Stimulated t-PA Release
Pretorius M, Rosenbaum DA, Lefebvre J, Vaughan DE, Brown NJ. Smoking Impairs Bradykinin-Stimulated t-PA Release. Hypertension 2002, 39: 767-771. PMID: 11897760, DOI: 10.1161/hy0302.105767.Peer-Reviewed Original ResearchConceptsTissue plasminogen activator releaseTissue plasminogen activator responsePlasminogen activator releaseForearm blood flowDose-dependent increaseActivator releaseBlood flowDoses of nitroprussideSignificant dose-dependent increaseActivator responseStrain-gauge plethysmographyBody mass indexEffect of bradykininT-PA releaseReceptor-dependent mechanismEndothelial functionBrachial arteryMass indexMethacholineSmokersNonsmokersBradykininHuman endotheliumRandom orderSignificant differences
2001
Quantification of BK1-5, the Stable Bradykinin Plasma Metabolite in Humans, by a Highly Accurate Liquid-Chromatographic Tandem Mass Spectrometric Assay
Murphey L, Hachey D, Vaughan D, Brown N, Morrow J. Quantification of BK1-5, the Stable Bradykinin Plasma Metabolite in Humans, by a Highly Accurate Liquid-Chromatographic Tandem Mass Spectrometric Assay. Analytical Biochemistry 2001, 292: 87-93. PMID: 11319821, DOI: 10.1006/abio.2001.5073.Peer-Reviewed Original Research
2000
Endogenous bradykinin and the renin and pressor responses to furosemide in humans.
Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. Journal Of Pharmacology And Experimental Therapeutics 2000, 295: 644-8. PMID: 11046100.Peer-Reviewed Original ResearchConceptsPlasma renin activityMean arterial pressureHoe 140Renin responseEndogenous bradykininRenin activityArterial pressureHeart rateBasal plasma renin activityRenin-angiotensin systemAngiotensin I/Blood pressure regulationCrossover design studyAcute furosemide treatmentRenin regulationSpecific bradykininDiuretic responseFurosemide administrationFurosemide treatmentACE inhibitionReceptor antagonistPressure regulationBradykininFurosemideHumansMetabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite.
Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ. Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. Journal Of Pharmacology And Experimental Therapeutics 2000, 294: 263-9. PMID: 10871321.Peer-Reviewed Original ResearchConceptsBK1-5Stable metaboliteRole of bradykininMetabolism of bradykininDose of bradykininInfused bradykininBradykinin infusionVenous plasmaExogenous bradykininPlasma concentrationsPharmacologic alterationsSystemic circulationFmol/Total doseBradykinin generationPlasma metabolitesHuman volunteersBradykininDisease statesInfusionBloodDoseMetabolitesAmino acid fragmentHuman diseasesInhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans.
Kim KS, Kumar S, Simmons WH, Brown NJ. Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. Journal Of Pharmacology And Experimental Therapeutics 2000, 292: 295-8. PMID: 10604961.Peer-Reviewed Original ResearchConceptsDegradation of bradykininACE inhibitionWheal responseACE inhibitor quinaprilEffect of quinaprilNon-ACE pathwaysMetabolism of bradykininDose-response curveCardioprotective effectsIntradermal administrationIntradermal injectionOral administrationHealthy subjectsEnzyme inhibitorsSignificant interactionQuinaprilBradykininAminopeptidase PAngiotensinInhibitionAdministrationHuman skinPresent studyApstatinResponse
1999
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema
Blais C, Rouleau J, Brown N, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43: 293-302. PMID: 10596866, DOI: 10.1016/s0162-3109(99)00133-2.Peer-Reviewed Original ResearchConceptsDes-Arg9AE patientsC subjectsLife-threatening adverse reactionsEnzyme (ACE) inhibitor-associated angioedemaMetabolism of bradykininLocal inflammatory reactionEnzyme defectPreincubation of seraBK metabolismSensitive enzyme immunoassayB1 agonistSerum metabolismAdverse reactionsControl subjectsInflammatory reactionACEIAngioedemaAbnormal metabolismPatientsEnzyme inhibitorsSynthetic bradykininControl seraBradykininEnzyme immunoassayBradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature
Brown N, Gainer J, Stein C, Vaughan D. Bradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature. Hypertension 1999, 33: 1431-1435. PMID: 10373228, DOI: 10.1161/01.hyp.33.6.1431.Peer-Reviewed Original ResearchConceptsForearm blood flowPlasminogen activator inhibitor antigenTissue plasminogen activator releaseDose-dependent increasePlasminogen activator releaseTPA releaseInhibitor antigenBlood flowActivator releaseMean arterial pressureStrain-gauge plethysmographyHuman vasculatureInfused armNormotensive volunteersArterial pressureVasodilator nitroprussidePlasma levelsTPA antigenHeart rateSystemic effectsSodium nitroprussideAcetylcholineBradykininNitroprussideRandom order
1997
Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin
Brown N, Nadeau J, Vaughan D. Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin. Thrombosis And Haemostasis 1997, 77: 522-525. PMID: 9066005, DOI: 10.1055/s-0038-1656000.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBradykininCaptoprilFemaleHumansHypertensionIsoquinolinesMalePlasminogen Activator Inhibitor 1QuinaprilRandomized Controlled Trials as TopicTetrahydroisoquinolinesTissue Plasminogen ActivatorConceptsT-PA antigen levelsTissue-type plasminogen activatorMean arterial pressureT-PA levelsAntigen levelsPAI-1 antigen levelsInfusion of bradykininSympathetic nervous systemEffect of bradykininTissue-type plasminogen activator secretionHypertensive patientsHemodynamic effectsArterial pressurePlasminogen activator secretionAngiotensin IIAnimal modelsPotent stimulusNervous systemPAI-1ACEIBradykininBradykinin resultsSelective stimulationPlasminogen activatorSignificant decrease
1996
Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. Journal Of Pharmacology And Experimental Therapeutics 1996, 279: 703-12. PMID: 8930174.Peer-Reviewed Original ResearchConceptsACE inhibitorsVasodepressor responseProstacyclin responsesEnzyme inhibitorsHigh-renin hypertensive patientsContribution of prostacyclinPlacebo-treated subjectsMean arterial pressureProstaglandin-independent mechanismEffect of bradykininDegradation of bradykininBradykinin doseProstacyclin metaboliteHypertensive patientsHypotensive responseVasodepressor effectArterial pressureBlood pressureACE inhibitionPGF1 alphaUrinary excretionProstacyclin productionProstaglandin productionBradykininClass effectThe Renin-Angiotensin and Fibrinolytic Systems Co-Conspirators in the Pathogenesis of Ischemic Cardiovascular Disease
Brown N, Vaughan D. The Renin-Angiotensin and Fibrinolytic Systems Co-Conspirators in the Pathogenesis of Ischemic Cardiovascular Disease. Trends In Cardiovascular Medicine 1996, 6: 239-243. PMID: 21232303, DOI: 10.1016/s1050-1738(96)00091-6.Peer-Reviewed Original ResearchTissue-type plasminogen activatorFibrinolytic systemIschemic cardiovascular eventsRenin-angiotensin systemBreakdown of bradykininCardiovascular eventsAngiotensin IIT-PA secretionClinical observationsPotent stimulusStimulates releaseAngiotensin IPAI-1Plasminogen activatorVivo dataMajor inhibitorACEAngiotensinBradykininSecretionVasculature